VEEV Q2 Earnings & Revenues Beat Estimates, Margin Rises, Stock Up

Veeva Systems (VEEV) reported strong fiscal Q2 2026 results, with adjusted EPS of $1.99, up 22.8% year-over-year, and revenues of $789.1 million, up 16.7% year-over-year, both exceeding analyst estimates, primarily driven by robust subscription services growth. The company raised its full-year fiscal 2026 revenue guidance to $3.134-$3.140 billion and adjusted EPS to $7.78, reflecting continued momentum from its Vault CRM Suite's expansion, new major biopharma client wins, strategic AI integration, and a long-term partnership with IQVIA.

Analysis

Veeva Systems (VEEV) delivered a robust performance in its fiscal second quarter of 2026, demonstrating significant operational momentum and strategic execution. The company reported a 22.8% year-over-year increase in adjusted EPS to $1.99 and a 16.7% rise in revenue to $789.1 million, surpassing consensus estimates by 4.74% and 2.8%, respectively. This growth was primarily fueled by a 17.4% increase in its high-margin Subscription services segment, which reached $659.2 million. Profitability also improved, with gross margin expanding 50 basis points to 75.3% and operating margin widening by 20 basis points to 24.8%, despite a notable 56.1% surge in general and administrative expenses. Management's confidence is underscored by its upwardly revised full-year fiscal 2026 guidance, with revenue now projected at $3.134-$3.140 billion and adjusted EPS at $7.78, both exceeding prior forecasts and current analyst expectations. Key strategic developments underpin this positive outlook, including significant customer wins for its Vault CRM Suite, which now serves over 100 customers and seven of the top 20 biopharmas. Furthermore, the resolution of legal disputes and subsequent partnership with IQVIA removes a major overhang, while the clear product roadmap for Veeva AI, with initial agents launching in December, positions the company to capitalize on a key industry trend.

Key Decisions for Investors

• The strong beat-and-raise quarter, coupled with significant market share gains in top biopharma, provides a fundamental basis for a continued bullish outlook on VEEV, justifying the stock's 39.7% year-to-date outperformance.
• Investors should monitor key catalysts including the adoption rate and client feedback for the first Veeva AI agents launching in December and the continued conversion of major biopharma clients to the Vault CRM platform.
• While the resolution of the IQVIA litigation de-risks the investment, the sharp 56.1% YoY increase in G&A expenses warrants scrutiny in subsequent quarters to ensure operating leverage is maintained.
• Given the company's strong financial position with $6.4 billion in cash and short-term investments, investors should assess potential capital allocation strategies, such as further investment in R&D or strategic acquisitions.